Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Curtis A Lachowiez, Joshua F Zeidner, Ashley M. Eckel, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 62.

https://doi.org/10.1182/blood-2024-201532

Published: 2024

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

Journal Articles

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Blood (2024) 144 (Supplement 1): 685.

https://doi.org/10.1182/blood-2024-194414

Published: 2024

Journal Articles

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Justin M. Darrah, Indumathy Varadarajan, Amitkumar Mehta, Jennifer N. Saultz, Matthew McKinney, Monalisa Ghosh, Usama Gergis, Girish Bende, Siddha Kasar, Bradley Hupf, Sharon Chen, Leopold Sellner, Reem Karmali

Blood (2024) 144 (Supplement 1): 95.

https://doi.org/10.1182/blood-2024-194807

Published: 2024

Journal Articles

Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

Daniel J. Chandra, Faith Burns, Austin Nguyen, Elias Pavlatos, Khauan Bainha, Nicola Long, Yoko Kosaka, Jessica Mulkey, Joanna Pucilowska, Evan F. Lind, Jeffrey W. Tyner, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4815.

https://doi.org/10.1182/blood-2024-199437

Published: 2024

Journal Articles

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Vishvaas I Ravikumar, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Mael Heiblig, Joshua F Zeidner, Daniel A Pollyea, Curtis A Lachowiez

Blood (2024) 144 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2024-201231

Published: 2024

Journal Articles

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Uma Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel J. Cook, Jennifer N. Saultz, Ronan T. Swords, Nicole R. Grieselhuber, Alice Mims, Karilyn T. Larkin, Kieran D Sahasrabudhe, James S. Blachly, Gregory K Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L Koenig

Blood (2024) 144 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2024-210605

Published: 2024

Journal Articles

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Jennifer N. Saultz, Manoj Rai, Andy Kaempf, Sanjog Bastola, Hyun Cho, Nicola Long, Curtis A. Lachowiez, Gabrielle Meyers, Jessica T. Leonard, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner

Blood (2024) 144 (Supplement 1): 2859.

https://doi.org/10.1182/blood-2024-211860

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Somya Khare, Rachel J. Cook, Amrita Desai, Arpita Gandhi, Kelli Goslee, Brandon Hayes-Lattin, Curtis A Lachowiez, Jessica T. Leonard, Richard T. Maziarz, Gabrielle Meyers, Laura F. Newell, Jennifer N. Saultz, Ronan T. Swords, Elie Traer, Eneida R Nemecek

Blood (2024) 144 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2024-209407

Published: 2024

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2024-203361

Published: 2024

Journal Articles

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2024-208505

Published: 2024

Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea

Blood blood.2024026925.

https://doi.org/10.1182/blood.2024026925

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Rashmi Khanal, Jennifer N. Saultz, Umar Farooq, Sunita Nathan, Amitkumar Mehta, Ayad Hamdan, Lawrence E. Morris, Jr., Houston Holmes, Lauren C. Pinter-Brown, John K.C. Lim, Amanda Conerty, Heather Raymon, Peter Flynn, Anita G. Seto, Joseph J. Maly

Blood (2022) 140 (Supplement 1): 12742–12743.

https://doi.org/10.1182/blood-2022-159282

Published: 2022

NARROW

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Characterizing the Role of Interferon-γ Signaling in Natural Killer Cell Dysfunction in Venetoclax-Resistant Acute Myeloid Leukemia

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Trial in Progress: AB-101, an Allogeneic, Non-Engineered, Cord Blood-Derived Natural Killer (NK) Cell Therapy, As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only